ReviewBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2025
MicroRNA-128-3p as a promising target in neuropsychiatric disorders: From epigenetics to pharmacological intervention.
Review in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Flunarizine changes microRNA expression in cell cultures and in a mouse model of spinal muscular atrophy.Scientific reports · 2026Article
- Identification and functional characterization of plasma exosomal miR-618 as a novel biomarker in recurrent depressive disorder.Frontiers in pharmacology · 2026Article
- Silent regulators of trauma: the microRNA blueprint underlying post-traumatic stress disorder biology.Environmental epigenetics · 2026Review
- Stress-Associated Changes in MiR-20b-3p as a Potential Predictor of Underlying Psychopathology in the Depressed Brain: Mechanistic Insights from a Rat Model of Chronic Restraint Stress.Molecular neurobiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Major depressive disorder (MDD) is a leading neuropsychiatric condition associated with significant morbidity and mortality worldwide. Epigenetic mechanisms are key factors involved in the development of MDD, with microRNAs (miRNAs) serving as important epigenetic regulators in this process. Increasing evidence suggests that approximately 70 % of miRNA is expressed in the brain, playing a crucial role in various brain functions. Aberrant changes in miRNA expression are frequently associated with the pathophysiology of stress-related neuropsychiatric disorders, including MDD. One notable stress-responsive miRNA is miR-128, which is highly expressed in the brain and involved in numerous functions, such as neural development, signaling pathways, neuronal migration, neural plasticity, and neurogenesis. The significant role of this miRNA positions it as a critical candidate for increased susceptibility to stress. So far, the role of miR-128 has been reported in various neurodegenerative disorders; however, studies examining its involvement in neuropsychiatric disorders are gaining traction. More specifically, miR-128 has been shown to influence the Wnt signaling pathway, potentially leading to depression-like behavior. In this review, we critically evaluate the functions of miR-128, with a particular focus on its regulatory mechanisms, target gene expression, and downstream signaling pathways. Additionally, we provide a comprehensive assessment of miR-128-3p regarding its potential involvement in the pathogenesis of MDD and its possible role as a disease and treatment biomarker. This exploration may unveil new avenues for innovative diagnostic approaches and treatment strategies in MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.